Clinical trials
Phase 1 Skin Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2014 | 4 |
| 2016 | 3 |
| 2018 | 4 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 9 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Recruiting | 11 |
| Active, not recruiting | 7 |
| Terminated | 7 |
| Unknown status | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| H. Lee Moffitt Cancer Center and Research Institute | 8 |
| Case Comprehensive Cancer Center | 2 |
| Immorna Biotherapeutics, Inc. | 2 |
| National Cancer Institute (NCI) | 2 |
| Revolution Medicines, Inc. | 2 |
| Roswell Park Cancer Institute | 2 |
| Ankyra Therapeutics, Inc | 1 |
| BIND Therapeutics | 1 |
| BioNTech US Inc. | 1 |
| Brian Henick, MD | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Skin Neoplasms | 56 |
| Melanoma | 22 |
| Neoplasms | 16 |
| Lung Neoplasms | 13 |
| Carcinoma, Non-Small-Cell Lung | 12 |
| Breast Neoplasms | 10 |
| Basal Cell Carcinoma | 9 |
| Head and Neck Neoplasms | 9 |
| Neoplasm Metastasis | 8 |
| Urinary Bladder Neoplasms | 8 |
Trials
Showing 1 to 25 of 56. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.